112 related articles for article (PubMed ID: 3857643)
21. Cardioprotective actions of a selective thromboxane synthetase inhibitor in acute myocardial ischemia.
Burke SE; Lefer DJ; Lefer AM
Arch Int Pharmacodyn Ther; 1983 Sep; 265(1):76-84. PubMed ID: 6686001
[TBL] [Abstract][Full Text] [Related]
22. Testing the "redirection hypothesis" of prostaglandin metabolism in the kidney.
Datar S; McCauley FA; Wilson TW
Prostaglandins; 1987 Feb; 33(2):275-85. PubMed ID: 3296006
[TBL] [Abstract][Full Text] [Related]
23. Possible role of thromboxane A2 in remote hind limb preconditioning-induced cardioprotection.
Sharma R; Randhawa PK; Singh N; Jaggi AS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jan; 389(1):1-9. PubMed ID: 26531833
[TBL] [Abstract][Full Text] [Related]
24. Thromboxane synthetase inhibitors reduce infarct size by a platelet-dependent, aspirin-sensitive mechanism.
Mullane KM; Fornabaio D
Circ Res; 1988 Apr; 62(4):668-78. PubMed ID: 3127073
[TBL] [Abstract][Full Text] [Related]
25. Improved lactate extraction in dogs with coronary artery ligation following administration of a thromboxane synthetase inhibitor.
Eddy LJ; Oei HH; Glenn TM
Res Commun Chem Pathol Pharmacol; 1983 Jan; 39(1):87-97. PubMed ID: 6682567
[TBL] [Abstract][Full Text] [Related]
26. TxA2 inhibition and ischemia-induced loss of myocardial function and reactive hyperemia.
Mehta JL; Nichols WW; Schofield R; Donnelly WH; Chandna VK
Am J Physiol; 1990 May; 258(5 Pt 2):H1402-8. PubMed ID: 2159727
[TBL] [Abstract][Full Text] [Related]
27. Reduction of infarct size and infiltration of polymorphonuclear leukocytes by a thromboxane synthetase inhibitor. Studies in a rabbit ischemic heart model.
Ito T; Asai F; Ushiyama S; Matsuda K; Oshima T
Arzneimittelforschung; 1990 Jan; 40(1):23-7. PubMed ID: 1692704
[TBL] [Abstract][Full Text] [Related]
28. Development of an experimental model of acute myocardial infarction and the effects of a thromboxane synthetase inhibitor (OKY-046).
Tomoda H
Am Heart J; 1986 Oct; 112(4):696-704. PubMed ID: 3532743
[TBL] [Abstract][Full Text] [Related]
29. Beneficial effects of U-63,557A, a thromboxane synthetase inhibitor, in an ovine model of pregnancy-induced hypertension.
Keith JC; Thatcher CD; Schaub RG
Am J Obstet Gynecol; 1987 Jul; 157(1):199-203. PubMed ID: 3605254
[TBL] [Abstract][Full Text] [Related]
30. Effect of the thromboxane receptor antagonist SQ 29,548 on myocardial infarct size in dogs.
Grover GJ; Schumacher WA
J Cardiovasc Pharmacol; 1988 Jan; 11(1):29-35. PubMed ID: 2450253
[TBL] [Abstract][Full Text] [Related]
31. Anti-ischemic actions of a new thromboxane receptor antagonist during acute myocardial ischemia in cats.
Brezinski ME; Yanagisawa A; Darius H; Lefer AM
Am Heart J; 1985 Dec; 110(6):1161-7. PubMed ID: 3000159
[TBL] [Abstract][Full Text] [Related]
32. Effects of the new class I antiarrhythmic agent Ro 22-9194, (2R)-2-amino-N-(2,6-dimethylphenyl)-N-[3-(3-pyridyl)propyl]propionamide D-tartrate, on ischemia- and reperfusion-induced arrhythmias in dogs: involvement of thromboxane A2 synthase inhibitory activity.
Murakami M; Kinukawa M; Kanazawa T; Maruyama K; Miyagi M; Miyata H; Ujiie A
J Pharmacol Exp Ther; 1996 Nov; 279(2):877-83. PubMed ID: 8930195
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
34. The effect of beta-adrenoceptor blockade and of thromboxane synthetase inhibition, alone and in combination, on arrhythmias resulting from myocardial ischemia.
Wainwright CL; Parratt JR
Adv Myocardiol; 1985; 6():573-84. PubMed ID: 4039460
[TBL] [Abstract][Full Text] [Related]
35. Effects of a thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias after coronary artery occlusion and reperfusion in dogs.
Sato N; Endo T; Kiuchi K; Hayakawa H
J Cardiovasc Pharmacol; 1993 Mar; 21(3):353-61. PubMed ID: 7681494
[TBL] [Abstract][Full Text] [Related]
36. In vivo inhibition of thromboxane synthetase in infarcted canine myocardium.
McCluskey ER; Kramer JB; Corr PB; Needleman P
Biochem Biophys Res Commun; 1984 Jun; 121(2):552-7. PubMed ID: 6539597
[TBL] [Abstract][Full Text] [Related]
37. The effect of the thromboxane A2/prostaglandin endoperoxide receptor antagonist SQ 30,741 on myocardial infarct size and blood flow during myocardial ischemia and reperfusion.
Grover GJ; Schumacher WA; Simon M; Parham C
J Cardiovasc Pharmacol; 1988 Dec; 12(6):701-9. PubMed ID: 2467089
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3'-pyridinylmethyl)benzofuran-2-carboxylate.
Gorman RR; Johnson RA; Spilman CH; Aiken JW
Prostaglandins; 1983 Aug; 26(2):325-42. PubMed ID: 6316421
[TBL] [Abstract][Full Text] [Related]
39. BM 13.505, a selective thromboxane receptor antagonist, reduces myocardial infarct size following coronary artery reperfusion.
Smith EF; Earl CQ; Egan JW
Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):15-23. PubMed ID: 2532749
[TBL] [Abstract][Full Text] [Related]
40. Tissue-type plasminogen activator alone or in combination with thromboxane A2 synthetase inhibitor for ischemic myocardium.
Ogawa T; Miura T; Tsuchida A; Iwamoto T; Urabe K; Endoh A; Iimura O
Can J Cardiol; 1990 Oct; 6(8):361-6. PubMed ID: 2125235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
